Olmedipin Plus (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmedipin Plus, is a combination antihypertensive presented as a tablet for oral use. It treats hypertension in adults, often when single‑agent therapy is insufficient. GNH USA supplies Olmedipin Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmedipin Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmedipin Plus is a combination antihypertensive that addresses elevated blood pressure through multiple pathways. - Hypertension: helps achieve target blood pressure when monotherapy does not provide adequate control. - Hypertensive urgency: may be used as part of a regimen to lower blood pressure safely under medical supervision. - Cardiovascular risk reduction: contributes to lowering the risk of stroke and myocardial infarction in patients with high blood pressure.

Olmedipin Plus may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headedness - Peripheral edema, especially of the lower legs - Headache - Fatigue - Increased urination - Mild electrolyte disturbances (e.g., low potassium)

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia or severe electrolyte imbalance - Angio‑edema, particularly facial or airway swelling - Liver function abnormalities - Blood dyscrasias such as neutropenia

When prescribing Olmedipin Plus, clinicians should consider several safety aspects. - Renal function: assess baseline kidney function and monitor periodically. - Electrolytes: check serum potassium and sodium levels, especially with diuretic component. - Cardiovascular status: avoid rapid blood‑pressure drops in patients with recent myocardial infarction. - Pregnancy: contraindicated in the second and third trimesters; use only if benefits outweigh risks. - Drug interactions: review concomitant medications for additive hypotensive effects. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Olmedipin Plus can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of severe hypotension and renal impairment. - Potassium‑sparing diuretics or supplements: may cause dangerous hyper‑kalemia. - Lithium: increased lithium levels and potential toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive efficacy and affect renal function. - CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): can raise amlodipine concentrations. - Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.